The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery

PURPOSE: Bariatric surgery is nowadays commonly applied as treatment for morbid obesity (BMI > 40 kg/m(2)). As information about the effects of this procedure on a drug’s pharmacokinetics is limited, we aimed to evaluate the pharmacokinetics of CYP3A probe substrate midazolam after oral and intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Margreke J., van Rongen, Anne, van Dongen, Eric P., van Ramshorst, Bert, Hazebroek, Eric J., Darwich, Adam S., Rostami-Hodjegan, Amin, Knibbe, Catherijne A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628089/
https://www.ncbi.nlm.nih.gov/pubmed/26202517
http://dx.doi.org/10.1007/s11095-015-1752-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628089/
https://www.ncbi.nlm.nih.gov/pubmed/26202517
http://dx.doi.org/10.1007/s11095-015-1752-9

Ejemplares similares